ArticleBlood advances2026
Outcomes of relapsed or refractory acute myeloid leukemia after menin inhibition failure.
Article in Blood advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- The case for prospective MEN1 surveillance in the era of sequential menin inhibitor therapy.Leukemia · 2026Article
- Menin Inhibitors in Acute Myeloid Leukemia: Clinical Integration, Resistance, and the Path Beyond Monotherapy.Cancers · 2026Review
- Clinical research progress of menin inhibitors for acute myeloid leukemia: latest updates from the 2025 ASH Annual Meeting.Experimental hematology & oncology · 2026Article
- Overcoming MEN1-mediated resistance with menin inhibitor switching in KMT2A-rearranged acute myeloid leukemia.Leukemia · 2026Article
- Resistance to Targeted Therapy in AML: Current Challenges and Emerging Treatment Strategies.Journal of clinical medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
abstractMenin inhibitors (MENINi) show promise for relapsed or refractory (R/R) acute myeloid leukemia (AML) with KMT2A rearrangements (KMT2Ar) and nucleophosmin 1 mutations (NPM1c). Outcomes after MENINi failure are poorly understood. To characterize the mutational landscape and subsequent outcomes, we conducted a multicenter retrospective study of adults from 4 US centers with R/R AML after MENINi failure (relapse after response or primary refractory). The 84 patients (63% KMT2Ar, n = 53; 23% NPM1c, n = 19) who received MENINi were heavily pretreated: 86% (n = 72) had previous intensive chemotherapy (IC) and 77% venetoclax (VEN; n = 67). After MENINi failure, 40% of patients (n = 34) received supportive care. For the treated patients (n = 50), common regimens included hypomethylating agent (HMA)/VEN (26%, n = 13), clinical trial (26%, n = 13), and gilteritinib-based therapy (18%, n = 9). The complete response (CR)/CR with incomplete hematologic recovery (CRi) rate for nontrial therapies was 19% (n = 7); overall response rate was 32% (n = 12). All CR/CRi occurred with HMA/VEN (n = 2, 15%), IC + VEN (n = 4, 67%), or MENINi switching (bleximenib to revumenib, n = 1 [50%]). No patient with FLT3-ITD mutation responded to gilteritinib (0/6 gilteritinib-naïve). Median overall survival from start of next therapy was 4.4 months and superior for patients who achieved CR/CRi, (15.4 vs 3.4 months, P = .048). Outcomes after MENINi failure are poor, but responses occur with VEN-based regimens or MENINi switching. FLT3-ITD, WT1, and MEN1 mutations are associated with resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.